## 4 Database, Available Features and Target to Be Forecasted  
### Description of the Experiment  
In order for this research to harvest a complete empirical collection of features, we created a new dataset by employing new ways of monitoring subjects. The glycaemia of 25 subjects underwent continuous monitoring for up to 14 days as they went about their normal routines. This monitoring campaign was awarded approval by the Ethical Research Commission of the University of Murcia on 25 January 2018 (Id.16 83/2017). Each volunteer suffers DM1 being treated with a basal-bolus strategy, either employing slow insulin like Lantus, Levemir or Lantus--which creates a flat action curve--or fast insulin like Humalog-Lispro. Using slow insulin in basal coverage lasts for over 24 h; fast insulin is used to counter rises in glycaemia which may occur when eating or to counter hyperglycemia arising from other causes. Each subject signed an informed consent form prior to participation in the research. There were 11 women and 14 men in the study cohort, each one receiving professional supervision and medical care. The monitoring undertaken was of a passive form that made no intervention in patient treatment, with every subject advised to continue with the instructions of their physicians. The subjects ranged from 18- to 56-year-olds, with an average age of 24.51 years, with the majority of subjects falling into the young adult category. All patients had been suffering from diabetes for a minimum of five years; this time was set to ensure all patients had familiarity with the way the disease progresses. All subjects were given complete information regarding the research aims. Generally, the subjects' condition was well controlled, all of them having a glycated hemoglobin(hbA1c) of between 6% and 7% when the experiment began. Every patient claimed to be leading a healthy lifestyle, with none of them undertaking fewer than three sporting activities per week. Some scheduling was factored in in an attempt to make sure that every patient was following some form of routine without making drastic alterations to their daily routines. Each subject consumed a balanced diet that met their calorific needs. Subjects were asked to maintain their usual life habits and to continue following their endocrinologist's advice. The patients in this research were given CGM sensors to wear, the model being the Freestyle Libre made by Abbott Company. This revolutionary device comprises a patch and a measuring device, permitting patients to make simple checks of their glycemic state (interstitial-glucose levels rather than blood-glucose levels). A notable feature of this device is that it allows the patient to check their glucose levels as frequently as they wish and collect data every 60 s. This device has been quite revolutionary as it is economically priced and achieves a reasonable level of accuracy (11.4% Mean Absolute Relative Difference, MARD). The subjects were asked to note down what fast-insulin dosages that had slow-insulin dosages, and also the carbohydrates they consumed through food, meaning that the data were empirical rather than subjective. The CGM has a maximum lifespan of 14 days, but it can cease functioning prior to that. As it cannot be reattached once it has fallen off, it can cease working through accident, failed adhesion, or excessive humidity. In addition, the initial days of use can be inaccurate as the calibration is not solidified. It was proposed that data should be harvested from nine days of the usage period, with the initial days being excised as calibration was still taking place, and the final one is excised as the device may not have been able to cover the full 14-day lifespan. Thus, the experimental phase had 5400 h of data to consider. Freestyle Libre is a device using flash glucose monitoring. Glucose levels are transmitted instantaneously when required, employing Near Field Communication (NFC) which needs the patient to actively require the data.